Form 4: MAIA Biotechnology Executive Sergei Gryaznov Reports Stock Option Grant

Chief Scientific Officer Sergei Gryaznov reports the acquisition of stock options in MAIA Biotechnology, Inc.

Summary

• Sergei Gryaznov, Chief Scientific Officer of MAIA Biotechnology, Inc., filed a Form 4 on April 30, 2024.
• The filing reports the grant of stock options to Gryaznov on April 26, 2024.
• Gryaznov acquired 141,000 stock options with an exercise price of $2.94.
• The options vest over a 4-year period, with 25% vesting on the first anniversary and the remainder vesting monthly over the following 36 months.
• The options expire on April 26, 2034.

Sentiment

Score: 5

Explanation: Neutral sentiment as it is a routine disclosure of executive compensation.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to incentivize performance and retain key personnel.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded biotechnology companies.
• The vesting schedule of 4 years with a 1-year cliff is a typical structure to ensure long-term commitment.
• The size of the grant (141,000 options) would need to be compared to grants made to executives at peer companies of similar market capitalization and stage of development to assess its relative value.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised.
• The grant incentivizes the executive to increase shareholder value.

Key Dates